Lupin Share Price
CMP as on 24-Nov-20 10:06
₹ 888.10Open
₹ 887.75Turnover (lac)
₹ 4,163Prev. Close
₹ 884.30Day's Vol (shares)
₹ 4,68,734CMP as on24-Nov-20 10:06
₹ 886.90Open
₹ 890.00Turnover (lac)
₹ 1,822Prev. Close
₹ 883.95Day's Vol (shares)
₹ 10,915CMP as on 24-Nov-20 10:06
₹ 887.90Open
₹ 889.00Open Interest(Contracts)
₹ 69,07,100VWAP
₹ 890.87Day's Vol (shares)
₹ 7,24,200News
-
Nifty Pharma in the fast lane; Dr Reddy's outperforms by 4%
14:36 IST, Nov 23The index has also touched an intraday high of 11,835.65.
-
Aurobindo Pharma and Dr Reddy's drag Nifty Pharma in wake of patent infringement
13:33 IST, Nov 18The US drugmaker has filed a patent infringement case in the District of Delaware against Aurobindo in a district court.
-
Nifty Pharma under pressure; Torrent Pharma, Lupin, Biocon drag the performance
15:09 IST, Nov 17Pfizer Inc and its group companies have filed a petition against Aurobindo Pharma Ltd and Dr Reddys Laboratories in a US court.
-
Nifty Pharma index soars over 1% after FM's unveils new stimulus package; Torren
15:00 IST, Nov 13Of the total PLI scheme, an outlay of Rs15,000cr is set for pharmaceuticals and drugs sector.
-
Lupin's alliance partner Concord receives USFDA nod for Tacrolimus Capsules
15:06 IST, Nov 12Tacrolimus Capsules USP are indicated for the prophylaxis of organ rejection in adult and pediatric patients.
-
Bulls of Wednesday! Nifty Pharma outperforms 3%; Aurobindo Pharma, Lupin top gai
13:26 IST, Nov 11The sector limited losses in benchmarks Sensex and Nifty which have pared early gains and were trading flat led by selling in heavyweig
-
Sensex, Nifty retreat from record highs; auto, pharma, banks stocks drive invest
11:19 IST, Nov 11Auto, healthcare and banking stocks were top performers, driving the benchmarks.
-
Nifty Pharma index nosedives by 4% despite Covid-19 vaccine hopes rise; Cipla, C
14:52 IST, Nov 10Drugmaker Pfizer achieved success in the first interim analysis from the Phase 3 study.
-
USFDA inspection of Lupin's Somerset facility; stock dip marginally
10:00 IST, Nov 09The inspection commenced on September 10, 2020, and concluded on November 5, 2020.
-
Novel Laboratories concludes USFDA inspection with 13 observations
9:55 IST, Nov 09Novel Laboratories concludes USFDA inspection with 13 observations
